Tag Archives: encorafenib

June, 2018

5 June
Array Announces Additional Median Overall Survival Results of Encorafenib and Binimetinib in Patients with Braf-Mutant Advanced Melanoma

BOULDER, Colo., June 4, 2018 /PRNewswire/ — Array BioPharma Inc. (NASDAQ: ARRY) today announced updated results from the Phase 3 COLUMBUS trial in BRAF-mutant advanced melanoma. The results showed median overall survival (mOS) was 33.6 months for patients treated with the combination of encorafenib and binimetinib compared to 16.9 months for patients treated with vemurafenib as …
Share

13 September
FDA to Review Array BioPharma’s NDAs for Binimetinib and Encorafenib for Advanced BRAF-Mutant Melanoma

BOULDER, Colo., Sept. 12, 2017 /PRNewswire/ — Array BioPharma (Nasdaq: ARRY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Applications (NDAs) to support use of the combination of binimetinib 45 mg twice daily and encorafenib 450 mg once daily (COMBO450) for the treatment of patients with BRAF-mutant advanced, …
Share

26 January
Array BioPharma Gains Rights to Novartis’ Cancer Candidate

BioPharma has struck a deal with Novartis Pharma AG for rights to an investigational cancer drug. Array recently announced that it has entered into a definitive agreement with Novartis to acquire worldwide rights to encorafenib (LGX818), Novartis’ BRAF inhibitor in development for treatment of skin and colorectal cancer. The deal …
Share